RXi and Karolinska Institutet target solid tumour therapy
US-based biotechnology company RXi Pharmaceuticals has formed a research alliance with the Karolinska Institutet in Stockholm, Sweden, to develop and…
solid tumours
-
-
Seattle Children’s launches new CAR T-cell immunotherapy trial
US-based Seattle Children’s has initiated a Phase I clinical trial to treat solid tumours using chimeric antigen receptor (CAR) T-cell…
-
Boehringer Ingelheim acquires MabVax’s programme for solid tumours
Boehringer Ingelheim has entered an asset acquisition and licence agreement for US-based biotechnology firm MabVax Therapeutics’ programme designed to target…
